Dr. Myron Czuczman highlighted the significance of the recent U.S. Food and Drug Administration (FDA) approval of Lymphir ...
A team of researchers at VCU Massey Comprehensive Cancer Center discovered an innovative way to use a drug already approved ...
SurvivorNet on MSN
Targeted drug Epkinly is suddenly front & center in lymphoma care: Here’s what patients need to know
The FDA approved Epkinly in combination with other standard lymphoma drugs, rituximab + lenalidomide, for relapsed or ...
Eli Lilly Canada, Inc announced today that Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) is now approved and available ...
Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established ...
First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA® and rituximab regimen ...
Please provide your email address to receive an email when new articles are posted on . Most patients with B-cell lymphomas who relapsed after CAR T-cell therapy responded to the novel, ...
Low-grade lymphomas are a non-Hodgkin lymphoma (NHL) subtype. They typically grow more slowly and cause fewer symptoms than NHLs. They still require ongoing monitoring and treatment. There are two ...
The Global Peripheral T-Cell Lymphoma Market is poised for significant growth, driven by a rising incidence of lymphoma and adoption of novel targeted therapies and immunotherapies. Peripheral T-cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results